HSBC/CALL/GILEAD SCIENCES/120/0.1/15.01.25 | Market Closed - Börse Stuttgart 07:23:57 28/06/2024 BST | ||
| 0.001 EUR | -.--% |
|
| Current year | -96.15% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 28/06/24 | 0.001 | -.--% |
| 27/06/24 | 0.001 | -.--% |
| 26/06/24 | 0.001 | -.--% |
| 25/06/24 | 0.001 | -.--% |
| 24/06/24 | 0.001 | -.--% |
Delayed Quote Börse Stuttgart
Last update June 28, 2024 at 07:23 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | HSBC |
| WKN | HG80R2 |
| ISIN | DE000HG80R25 |
| Date issued | 02/02/2023 |
| Strike | 120 $ |
| Maturity | 15/01/2025 (199 Days) |
| Parity | 10 : 1 |
| Emission price | 0.33 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.32 € |
|---|---|
| Lowest since issue | 0.001 € |
| Spread | 0.015 € |
| Spread % | 65.22% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
68.61
USD
Average target price
82.97
USD
Spread / Average Target
+20.93%
- Stock Market
- Warrants
- Warrant
